Price
Target price
€2.21
€2.21
-2.200%
-0.05
-2.200%
-
27.09.24 / Tradegate
WKN: 520394 / Name: B.R.A.I.N. Biotechnology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
B.R.A.I.N. Biotechnology Research and Information Network AG Stock
A loss of -2.200% shows a downward development for B.R.A.I.N. Biotechnology Research and Information Network AG.
Pros and Cons of B.R.A.I.N. Biotechnology Research and Information Network AG in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of B.R.A.I.N. Biotechnology Research and Information Network AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| B.R.A.I.N. Biotechnology Research and Information Network AG | -2.200% | -21.631% | 27.746% | -50.337% | -39.286% | -77.900% | -80.749% |
| Formycon AG | 6.260% | 13.846% | 5.714% | -3.310% | -0.538% | 9.901% | 83.168% |
| MagForce AG | - | 0.000% | 0.000% | -82.143% | -37.500% | -99.984% | -99.989% |
| Ardelyx Inc. | 5.550% | 8.258% | 6.935% | 50.684% | 2.976% | 417.565% | 33.318% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-11
Based on the provided financials, it's observed that B.R.A.I.N Biotechnology has an interesting financial perspective. As a company in a rather volatile industry, Biotechnology, the financials of the firm showcase a unique blend of stability and potential areas of growth. However, they also reveal certain risks and possible weaknesses.
Vorteile (Pros)
In terms of market capitalization, B.R.A.I.N Biotechnology seems to be making steady strides. With a market capitalization of approximately 88.7 million, the company appears to have a stable market presence. It's also noteworthy that the company has continuously secured revenue, as indicated by the revenue TTM (Trailing Twelve Months) of 54.698 million.
Comments
News
EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
EQS-News: BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
EQS-News: BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year